Drug Type Small molecule drug |
Synonyms ASK120067 |
Target |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC29H32ClN7O2 |
InChIKeyQHPVTCLSVVUPOF-UHFFFAOYSA-N |
CAS Registry1934259-00-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | NDA/BLA | CN | 16 Nov 2021 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | CN | 23 Jul 2019 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 03 Jan 2018 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 03 Jan 2018 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 03 Jan 2018 | |
MET gene amplification Non-small Cell Lung Cancer | IND Approval | CN | 20 Nov 2023 |
NCT03502850 (ASCO2022) Manual | Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR T790M Mutation | 301 | hxbfvsmbzr(jihmydnkkp) = romtmbztng rllprhattd (qxbqkalpur, 63.2 - 74.0) View more | Positive | 02 Jun 2022 | |
(CNS metastases) | hxbfvsmbzr(jihmydnkkp) = mfmbjbtrmw rllprhattd (qxbqkalpur, 54.4 - 74.0) View more | ||||||
Phase 2 | 301 | dyaeqvwbjh(seoexwnzbn) = wwxbfipjkl pymxykibjf (dowghzagcn, 39.7% - 71.5%) View more | Positive | 02 Jun 2022 |